摘要
目的探讨缺血修饰白蛋白(IMA)水平对冠脉慢血流(CSF)治疗的临床意义。方法根据冠脉造影结果选取无冠状动脉狭窄但伴有冠状动脉血流缓慢者为CSF组(n=37),以冠脉造影正常者为对照组(n=20),比较CSF组与对照组IMA水平及CSF组治疗前后矫正的TIMI帧数(CTFC)及IMA水平。结果 CSF组共有78支血管受累,受累血管以右冠和左前降支多见,分别为84%和70%。与对照组比较,CSF组IMA值显著升高(P<0.01);CSF组治疗后IMA水平明显低于治疗前水平(P<0.01),且与CTFC改善程度呈正相关。结论 IMA检测可反映心肌组织缺血,操作简单,有望成为心肌缺血随访生化标志物。
Objective To observe the clinical significance of the level of ischemic modified albumin （IMA） in the patients with coronary slow flow （CSF）. Methods By coronary angiography,37 CSF patients were selected as the CSF group and 20 cases of normal coronary as the control group. The IMA value compared between two groups,CTFC and IMA levels were compared between before and after treatment in the CSF group. Results A total of 78 vessels were involved in CSF patients,in which right coronary artery and left anterior descending artery were 84% and 70% respectively. Compared with the control group,the IMA value in the CSF group was increased significantly （P〈0.01）. Compared with treatment before,the IMA level in the CSF group was significantly improved （P〈0.01） with decreased CTFC after treatment. Conclusion IMA value could detect the myocardial ischemia,the testing method might be simple,and it could be used as one of the biochemical markers of myocardial ischemia during follow-ups.
出处
《世界临床药物》
CAS
2010年第8期483-485,共3页
World Clinical Drug
